Zanco Journal of Medical Sciences
 
Skip Navigation Links
Home
Available Issues
Search
Editorial Board
Information for Authors
Review Process
Copyright
Links and Contacts
  Zanko J Med Sci:  Dec. 2017; 21 (3): 1869-1877

Measurements of serum high sensitivity-C reactive protein, and procalcitonin levels in type1 and 2 Diabetes complicated with diabetic foot syndrome

Zhian M.I. Dezayee *, Marwan S.M. Al-Nimer **

 

* Departmentof Microbiology, College of Health Sciences, Hawler Medical University, Erbil, Iraq.

** Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
 


Abstract

Background and objective: There is evidence that the procalcitonin levels are usually correlated with the high sensitivity C-reactive protein levels in inflammatory conditions. Therefore, this study aimed to assess the simultaneous changes of the procalcitonin and hs-CRP levels in the diabetic foot syndrome complicated type 1 and 2 diabetes.

Method: This observational study was carried in the Center of Diabetes Mellitus in Erbil, Iraq from 1st January to the 30th September 2015. A total number of 170 participants were enrolled in this study. They grouped into Group I (healthy subjects, n=30), Group II (type 1 diabetes with diabetic foot syndrome, n=70) and Group III (type 2 diabetes with diabetic foot syndrome, n=70). The anthropometric measurements, blood pressure, fasting serum glucose and lipid profile, and the inflammatory markers included high sensitivity C-reactive protein and procalcitonin were determined.

Results: Group III patients had a significant longer duration and score of diabetic foot syndrome, higher anthropometric measurements, higher blood pressure and fasting lipid profile levels compared with Group II. Serum procalcitonin and high sensitivity C-reactive protein levels were significantly higher in diabetic patients compared with Group I subjects. The serum levels of procalcitonin and high sensitivity C-reactive protein of Group III patients (1.11±0.47 ng/ml; 12.48±2.57 mg/L) were significantly higher than corresponding values of Group II patients (0.334±0.094 ng/ml; 5.73±0.89 mg/L). A non-significant correlation between procalcitonin with high sensitivity C-reactive protein in Group II and III was observed.

Conclusion: We conclude that the simultaneous measurements of high sensitivity C-reactive protein and procalcitonin as inflammatory biomarkers are not necessary because the correlation was not significant.

Keywords: Procalcitonin; High sensitivity C reactive protein; Diabetic foot syndrome.


Reference

1. Christ-Crain M, Muller B. Procalcitonin in bacterial infections--hype, hope, more or less? Swiss Med Wkly 2005; 135:451-60.

2. Uzun G, Solmazgul E, Curuksulu H, Turhan V, Ardic N, Top C, et al.Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med 2007; 213(4):305-12.

3. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014; 34(4): 263–73.

4. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomised control trial. Lancet 2010; 375(9713):463-74.

5. James WB. Classification of foot lesion in diabetic patients. In: Bowker JH, Pfeifer MA, eds, Levin and O’Neal’s The Diabetic Foot. 7th ed. Philadelphia: Mosby; 2008. P. 221-6.

6. Kocabaş ESarikçioğlu AAksaray NSeydaoğlu GSeyhun YYaman A. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis.Turk J Pediatr 2007; 49(1):7-20.

7. JonaidiJafari N, SafaeeFirouzabadi M, Izadi M, SafaeeFirouzabadi MS, Saburi A. Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers? Int J Endocrinol Metab 2014; 12(1):e13376.

8. Altay FASencan İŞentürk GÇ, Altay MGüvenman SÜnverdi Set al. Does treatment affect the levels of serum interleukin-6, interleukin-8 and procalcitonin in diabetic foot infection? A pilot study. J Diabetes Complications 2012; 26(3):214-8.

9. Wang C, Gao L, Zhang ZG, Li YQ, Yang YL, Chang T, et al. Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity C-reactive protein in patients with ischemic stroke. Mol Neurobiol 2016; 53(30):1509-17.

10. Li YM, Liu XY. Serum levels of procalcitonin and high sensitivity C-reactive protein are associated with long-term mortality in acute ischemic stroke. J Neurol Sci 2015; 352(1-2):68-73.

11. Villanueva MP, Mollar A, Palau P, Carratalá A, Núñez E, Santas E, et al. Procalcitonin and long-term prognosis after an admission for acute heart failure. Eur J Intern Med 2015; 26(1):42-8.

12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.

13. Boursier G, Avignon A, Kuster N, Boegner C, Leprieur E, Picandet M, et al. Procalcitonin, an Independent Marker of Abdominal Fat Accumulation in Obese Patients. Clin La 2016; 62:435-41.

14. Massara M, De Caridi G, Serra R, Barillà D, Cutrupi A, Volpe A, et al. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int Wound J 2017; 14(1):31-4.

15. Mutluoğlu M, Uzun G, İpcioğlu OM, Sildiroglu O, Özcan Ö, Turhan V, et al. Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study.Diabetes Res Clin Pract 2011; 94(1):53-6.

16. Mica L, Vomela J, Keel M, Trentz O. The impact of body mass index on the development of systemic inflammatory response syndrome and sepsis in patients with polytrauma. Injury 2014; 45(1):253-8.

17. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab 2010; 95(9):E26-31.

18. Mallamaci F, Leonardis D, Pizzini P, Cutrupi S, Tripepi G, Zoccali C. Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. J Hypertens 2013; 31(7):1424-30.

19. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003; 31(5):1359-66.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



Slightly know the replica watches uk fashionable women, even if you do not understand the replica watches also know that Cartier tanks, after all, this is the rolex replica royal family, film stars, literary celebrities, and rolex replica uk even political places are wearing watches.